Petco Health and Wellness Company, Inc. - Class A Common Stock (WOOF)
3.3200
-0.0600 (-1.78%)
Petco Health and Wellness Company is a leading provider of pet-related products and services, dedicated to enhancing the lives of pets and their owners
The company operates a network of retail stores offering a wide range of pet food, supplies, and health products, alongside grooming and veterinary services. Petco emphasizes a holistic approach to pet care, promoting wellness and preventive health solutions while also supporting pet adoption and rescue initiatives. With a commitment to the growing pet parent community, Petco endeavors to be a trusted resource for pet care, education, and overall pet health management.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Petco (NASDAQWOOF) and the rest of the specialty retail stocks fared in Q3.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the specialty retail industry, including National Vision (NASDAQEYE) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the specialty retail industry, including Leslie's (NASDAQLESL) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Tractor Supply (NASDAQTSCO) and the best and worst performers in the specialty retail industry.
Pet-focused retailer Petco (NASDAQWOOF) reported Q3 CY2024 results topping the market’s revenue expectations, with sales up 1.2% year on year to $1.51 billion. On the other hand, next quarter’s revenue guidance of $1.55 billion was less impressive, coming in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.02 per share was $0.01 above analysts’ consensus estimates.
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
